B · Normal
[Hengrui Medicine: The marketing application for a new indication of Hatrombopag ethanolamine tablets was accepted] On November 20, Hengrui Medicine (600276.SH) announced that the company received an "Acceptance Notice" issued by the State Food and Drug Administration, and the application for a new indication for marketing authorization of Hatrombopag ethanolamine tablets was accepted. The proposed indication is adult patients with chronic liver disease-related thrombocytopenia who plan to undergo elective invasive surgery. The application is based on a multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial. The study reached the primary research endpoint, and the experimental group was significantly better than the control group on the primary efficacy endpoint. Up to now, the cumulative R&D investment in this drug-related project is approximately 668 million yuan.
Comments